Black Diamond Therapeutics (BDTX) Expected to Release Quarterly Earnings on Thursday

Black Diamond Therapeutics (NASDAQ:BDTX) is expected to be posting its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Black Diamond Therapeutics to announce earnings of ($0.0550) per share and revenue of $8.33 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its earnings results on Wednesday, August 5th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.03. On average, analysts expect Black Diamond Therapeutics to post ($0.57) EPS for the current fiscal year and ($1.03) EPS for the next fiscal year.

Black Diamond Therapeutics Price Performance

Black Diamond Therapeutics stock opened at $1.83 on Thursday. Black Diamond Therapeutics has a one year low of $1.60 and a one year high of $4.94. The company’s fifty day moving average price is $1.96 and its two-hundred day moving average price is $2.20. The company has a market capitalization of $105.13 million, a price-to-earnings ratio of -2.44 and a beta of 3.32.

Analyst Ratings Changes

Several analysts have recently issued reports on BDTX shares. Jefferies Financial Group reiterated a “buy” rating on shares of Black Diamond Therapeutics in a research note on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Black Diamond Therapeutics in a report on Friday, October 9th. Wall Street Zen raised Black Diamond Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. TD Cowen reissued a “buy” rating on shares of Black Diamond Therapeutics in a research note on Thursday, August 6th. Finally, Raymond James Financial reaffirmed an “outperform” rating on shares of Black Diamond Therapeutics in a research report on Thursday, August 6th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Black Diamond Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company uses its proprietary MasterKey platform to identify and develop small-molecule therapies designed to address oncogenic mutations across multiple tumor types, including alterations that may be difficult to target with conventional approaches.

Black Diamond’s pipeline has included brain-penetrant therapies for cancers affecting the central nervous system.